New combo aims to shrink abdominal tumors for surgery
NCT ID NCT05185947
First seen May 30, 2026 · Last updated Jun 20, 2026 · Updated 4 times
Summary
This phase 2 trial tested a combination of two drugs—paclitaxel (given intravenously and directly into the abdomen) and oral nilotinib—in 21 adults with cancers (like colorectal, ovarian, or breast) that had spread to the lining of the abdomen and could not be surgically removed. The goal was to see if the treatment could shrink the tumors enough to make surgery possible. Participants received treatment in 3-week cycles and were monitored with laparoscopies and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Paclitaxel (Taxol) and nilotinib
What this could lead to
If successful, this combination could shrink widespread abdominal tumors enough to allow surgery, potentially improving survival for people with cancers that have spread to the lining of the abdomen.
What could go wrong
This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The treatment involves strong chemotherapy with side effects, and not all participants may respond well enough for surgery.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.